? The mission and infrastructure of the American College of Surgeons Oncology Group (ACOSOG) create relatively unique opportunities for the collection and analysis of human biospecimens for clinical correlative science studies. The group's surgical-trial focus allows for the prospective collection of fresh tissue specimens from operative procedures. Neoadjuvant trials conducted by the group facilitate the collection of biospecimens from treatment-naive patients and additional, serially timed specimens during the perioperative and post-operative (adjuvant) phase of treatment. Finally, the group's surgeon-based membership results in the recruitment of study participants and corresponding collection of biospecimens from a large number of primary, non-academic medical centers that are often not represented in other cooperative group studies. Accordingly, the goal of the ACOSOG Central Specimen Bank (ACOSOG-CSB) is to capitalize upon these unique features of ACOSOG to create a quality-controlled biospecimen repository with emphasis on frozen tissue specimens that are particularly well suited for molecular correlative science studies. To accomplish this goal, the ACOSOG-CSB and it's corresponding administrative group, the ACOSOG Tissue Bank Subcommittee, will support four main objectives. First, the ACOSOG-CSB will facilitate the collection of molecularly preserved biospecimens from patients enrolled on clinical trials. Emphasis will be placed on education and engagement of local pathologists in this effort. Second, the ACOSOG-CSB will serve as a central site for specimen storage, processing, and quality review. Best practices developed by the NCI Group Banking Committee (GBC) will be implemented as part of the bank's Standard Operating Procedures. Third, the ACOSOG-CSB will serve as a distribution center of specimens for both centralized pathology review and correlative science studies. In particular, the bank's existing expertise will be used to create assay-ready"""""""" materials (DNA and RNA) for correlative science studies. Fourth, members from the ACOSOG Tissue Bank Subcommittee will participate in the GBC, providing their unique experiences as related to developing standards for tissue procurement and informatics, and likewise benefiting from other cooperative group banking expertise. The long-term outcome of this effort will be the maturation of this Cooperative Group tissue bank into a biospecimen resource for the """"""""post-genomic era."""""""" ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA114736-04
Application #
7415166
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Lubensky, Irina
Project Start
2005-09-06
Project End
2010-03-31
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
4
Fiscal Year
2008
Total Cost
$340,041
Indirect Cost
Name
Duke University
Department
Surgery
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7
Ellis, Matthew J; Suman, Vera J; Hoog, Jeremy et al. (2017) Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol 35:1061-1069
Liu, Minetta C; Pitcher, Brandelyn N; Mardis, Elaine R et al. (2016) PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). NPJ Breast Cancer 2:
Miller, Christopher A; Gindin, Yevgeniy; Lu, Charles et al. (2016) Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun 7:12498
Goncalves, Rodrigo; Ma, Cynthia; Luo, Jingqin et al. (2012) Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer. Nat Rev Clin Oncol 9:223-9
Ellis, Matthew J; Suman, Vera J; Hoog, Jeremy et al. (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int J Clin Oncol 29:2342-9
Civantos, Francisco J; Zitsch, Robert P; Schuller, David E et al. (2010) Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. J Clin Oncol 28:1395-400